<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This prospective phase II study was undertaken to evaluate the efficacy and toxicity of early intensive therapy followed by purged autologous bone marrow transplantation (ABMT) in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received the VCAP regimen (<z:chebi fb="0" ids="36373">vindesine</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi>) as conventional chemotherapy and <z:chebi fb="0" ids="16108">DHAP</z:chebi> as second-line therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-nine consecutive patients were included in the study </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-seven patients were grafted, seven in first complete remission (CR) and 20 in first partial remission (PR) </plain></SENT>
<SENT sid="4" pm="."><plain>Preparative therapy consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and total body irradiation (TBI) in <z:hpo ids='HP_0000001'>all</z:hpo> the patients </plain></SENT>
<SENT sid="5" pm="."><plain>With a median follow-up of 6 years, the actuarial overall survival is 64% and the actuarial event-free survival is 55% </plain></SENT>
<SENT sid="6" pm="."><plain>Two treatment-related early <z:hpo ids='HP_0011420'>deaths</z:hpo> were observed </plain></SENT>
<SENT sid="7" pm="."><plain>Eleven patients were informative for serial PCR analysis of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> after ABMT: two relapsed, four remained disease-free with PCR positivity and five were disease-free with PCR negativity </plain></SENT>
<SENT sid="8" pm="."><plain>These encouraging results lay the basis of future prospective randomized trials comparing autologous stem cell transplantation as front-line treatment with conventional chemotherapy for patients with bad prognostic factors </plain></SENT>
</text></document>